266 related articles for article (PubMed ID: 29273915)
1. Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.
Lokvenc M; Kalinova M; Forsterova K; Klener P; Trneny M; Fronkova E; Kodet R
Ann Hematol; 2018 Mar; 97(3):467-474. PubMed ID: 29273915
[TBL] [Abstract][Full Text] [Related]
2. Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma.
Brizova H; Kalinova M; Krskova L; Mrhalova M; Kodet R
Int J Cancer; 2008 Dec; 123(12):2865-70. PubMed ID: 18798551
[TBL] [Abstract][Full Text] [Related]
3. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
[TBL] [Abstract][Full Text] [Related]
4. In situ hybridization and reverse transcription-polymerase chain reaction for cyclin D1 mRNA in the diagnosis of mantle cell lymphoma in paraffin-embedded tissues.
Athanasiou E; Kotoula V; Hytiroglou P; Kouidou S; Kaloutsi V; Papadimitriou CS
Mod Pathol; 2001 Feb; 14(2):62-71. PubMed ID: 11235907
[TBL] [Abstract][Full Text] [Related]
5. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas.
Medeiros LJ; Hai S; Thomazy VA; Estalilla OC; Romaguera J; Luthra R
Mod Pathol; 2002 May; 15(5):556-64. PubMed ID: 12011261
[TBL] [Abstract][Full Text] [Related]
6. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
[TBL] [Abstract][Full Text] [Related]
7. Real-time quantitative reverse transcription-PCR for cyclin D1 mRNA in blood, marrow, and tissue specimens for diagnosis of mantle cell lymphoma.
Howe JG; Crouch J; Cooper D; Smith BR
Clin Chem; 2004 Jan; 50(1):80-7. PubMed ID: 14633913
[TBL] [Abstract][Full Text] [Related]
8. Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH and immunohistochemistry.
Hui P; Howe JG; Crouch J; Nimmakayalu M; Qumsiyeh MB; Tallini G; Flynn SD; Smith BR
Leuk Lymphoma; 2003 Aug; 44(8):1385-94. PubMed ID: 12952233
[TBL] [Abstract][Full Text] [Related]
9. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
Miao Y; Wang R; Fan L; Qiu H; Wu Y; Chen Y; Xu W; Li J
Int J Clin Exp Pathol; 2015; 8(6):7494-8. PubMed ID: 26261659
[TBL] [Abstract][Full Text] [Related]
10. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
Drandi D; Ferrero S; Ladetto M
Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
[TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization.
Kodet R; Mrhalová M; Krsková L; Soukup J; Campr V; Neskudla T; Szépe P; Plank L
Virchows Arch; 2003 Jun; 442(6):538-47. PubMed ID: 12728315
[TBL] [Abstract][Full Text] [Related]
12. SOX11 as a minimal residual disease marker for Mantle cell lymphoma.
Simonsen AT; Sørensen CD; Ebbesen LH; Bødker JS; Bentzen HH; Nyvold CG
Leuk Res; 2014 Aug; 38(8):918-24. PubMed ID: 24878000
[TBL] [Abstract][Full Text] [Related]
13. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
[TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.
Chuang SS; Huang WT; Hsieh PP; Tseng HH; Campo E; Colomer D; Ye H; Lu CL; Chang HM; Cho CY; Huang SH; Lu YC; Wu JD
Pathol Int; 2006 Aug; 56(8):440-8. PubMed ID: 16872438
[TBL] [Abstract][Full Text] [Related]
15. Quantitative molecular analysis in mantle cell lymphoma.
Brízová H; Hilská I; Mrhalová M; Kodet R
Cesk Patol; 2011 Jul; 47(3):101-5. PubMed ID: 21887926
[TBL] [Abstract][Full Text] [Related]
16. Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation.
Menke JR; Vasmatzis G; Murphy S; Yang L; Menke DM; Tun HW; King RL; Smoley SA; Ketterling RP; Sukov WR
Hum Pathol; 2017 Jun; 64():207-212. PubMed ID: 28132860
[TBL] [Abstract][Full Text] [Related]
17. A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma.
Hamborg KH; Bentzen HH; Grubach L; Hokland P; Nyvold CG
Eur J Haematol; 2012 Nov; 89(5):385-94. PubMed ID: 22827557
[TBL] [Abstract][Full Text] [Related]
18. No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.
Vogt N; Abramov D; Koch K; Masqué-Soler N; Szczepanowski M; Klapper W
Leuk Lymphoma; 2015 Jul; 56(7):2134-40. PubMed ID: 25315075
[TBL] [Abstract][Full Text] [Related]
19. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.
Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F
Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
